Jefferies analyst Kevin Grundy raised the firm’s price target on Church & Dwight to $113 from $111 and keeps a Buy rating on the shares. The firm sees upside from Therabreath, with its work suggesting 15%-20% growth for the brand over the next five years, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHD:
- Church & Dwight price target raised to $95 from $85 at Stifel
- Church & Dwight price target raised to $105 from $96 at Deutsche Bank
- Church & Dwight price target raised to $91 from $83 at RBC Capital
- Church & Dwight price target raised to $83 from $79 at Barclays
- Church & Dwight narrows 2023 adjusted EPS growth view to 2%-4% from 0%-4%